O
ICPT

OrbiMed’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

OrbiMed’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-22,800
Closed -$2.83M – 165
2019
Q4 		$2.83M Sell
22,800
-9,400
-29% -$842K 0.04% 115
2019
Q3 		$2.14M Buy
+32,200
New +$2.16M 0.04% 106
2019
Q1 		– Sell
-47,800
Closed -$4.82M – 146
2018
Q4 		$4.82M Buy
+47,800
New +$4.95M 0.09% 101
2017
Q4 		– Sell
-386,380
Closed -$22.4M – 148
2017
Q3 		$22.4M Sell
386,380
-470,174
-55% -$50.6M 0.21% 81
2017
Q2 		$104M Sell
856,554
-180,446
-17% -$20.9M 1.09% 27
2017
Q1 		$117M Sell
1,037,000
-83,000
-7% -$9.69M 1.33% 24
2016
Q4 		$122M Hold
1,120,000
– – 1.55% 22
2016
Q3 		$184M Hold
1,120,000
– – 2.1% 9
2016
Q2 		$160M Hold
1,120,000
– – 1.67% 19
2016
Q1 		$144M Hold
1,120,000
– – 1.51% 22
2015
Q4 		$167M Hold
1,120,000
– – 1.51% 22
2015
Q3 		$186M Hold
1,120,000
– – 1.88% 18
2015
Q2 		$270M Hold
1,120,000
– – 2.26% 13
2015
Q1 		$316M Sell
1,120,000
-365,000
-25% -$79M 2.7% 10
2014
Q4 		$232M Hold
1,485,000
– – 2.21% 13
2014
Q3 		$351M Sell
1,485,000
-171,258
-10% -$43.7M 3.67% 5
2014
Q2 		$391M Sell
1,656,258
-78,676
-5% -$20.7M 4.59% 1
2014
Q1 		$572M Hold
1,734,934
– – 7.04% 1
2013
Q4 		$118M Sell
1,734,934
-416,673
-19% -$24.1M 1.74% 19
2013
Q3 		$149M Buy
2,151,607
+973
+0% +$48K 2.65% 10
2013
Q2 		$96.4M Buy
+2,150,634
New +$73.5M 2.04% 17

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

OrbiMed's ICPT Position: Q1 2020 in Review

OrbiMed sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2020, closing a stake of 22,800 shares — an estimated $2.83M sold.

OrbiMed first reported a position in ICPT in Q2 2013 and held it in 21 quarters. The position peaked at $572M in Q1 2014. 188 funds tracked by Wall St. Rank hold ICPT as of Q1 2020.

  • OrbiMed reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • OrbiMed sold 22,800 Intercept Pharmaceuticals, Inc. shares in Q1 2020, an estimated $2.83M.
  • OrbiMed first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 21 quarters.
  • OrbiMed's Intercept Pharmaceuticals, Inc. position peaked at $572M in Q1 2014.
  • 188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2020.

Based on OrbiMed's 13F filing for Q1 2020, filed 15 May 2020.